Emerging therapies for rheumatoid arthritis:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
1998
|
| Schriftenreihe: | Rheumatic disease clinics of North America
24,3 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | VIII S., S. 465 - 662 Ill., graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV012135573 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 980902s1998 ad|| |||| 00||| eng d | ||
| 035 | |a (OCoLC)39702247 | ||
| 035 | |a (DE-599)BVBBV012135573 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-12 | ||
| 050 | 0 | |a RC933 | |
| 245 | 1 | 0 | |a Emerging therapies for rheumatoid arthritis |c Joel M. Kremer, guest ed. |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 1998 | |
| 300 | |a VIII S., S. 465 - 662 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Rheumatic disease clinics of North America |v 24,3 | |
| 650 | 7 | |a Reumatoïde artritis |2 gtt | |
| 650 | 7 | |a Therapieën |2 gtt | |
| 650 | 4 | |a Arthritis, Rheumatoid |x therapy | |
| 650 | 0 | 7 | |a Rheumatoide Arthritis |0 (DE-588)4076708-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Rheumatoide Arthritis |0 (DE-588)4076708-5 |D s |
| 689 | 0 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Rheumatoide Arthritis |0 (DE-588)4076708-5 |D s |
| 689 | 1 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Kremer, Joel M. |e Sonstige |4 oth | |
| 830 | 0 | |a Rheumatic disease clinics of North America |v 24,3 |w (DE-604)BV000625464 |9 24,3 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008219304&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-008219304 | ||
Datensatz im Suchindex
| _version_ | 1804126744463015936 |
|---|---|
| adam_text | EMERGING THERAPIES FOR RHEUMATOID ARTHRITIS
CONTENTS
Preface xi
Joel M. Kremer
Triple Therapy with Methotrexate, Sulfasalazine, and
Hydroxychloroquine in Patients with Rheumatoid Arthritis 465
James R. O Dell
Combinations of DMARDs are currently used to treat rheumatoid
arthritis by almost all rheumatologists. This article reviews the
published data on the triple combination of methotrexate, sulfasa¬
lazine, and hydroxychloroquine, discusses caveats for clinical use,
compares efficacy of different combinations, and speculates on
future combination therapies.
The Use of Neoral in Rheumatoid Arthritis 479
Ann Cranney and Peter Tugwell
Neoral (a microemulsion based formulation) is an immunomodu
lator that possesses a more predictable and improved absorption
than the conventional oral formulation (Sandimmun). The in¬
creased bioavailability of Neoral could result in improved efficacy.
The pharmacokinetics of cyclosporin and efficacy of cyclosporin
in rheumatoid arthritis are reviewed in this article. Current guide¬
lines for the use of Neoral in the treatment of rheumatoid arthritis
patients are outlined.
Minocycline for the Treatment of Rheumatoid Arthritis 489
Graciela S. Alarcon
The scientific basis for the use of antibiotics (with special empha¬
sis on tetracycline and its derivatives) in the treatment of RA is
discussed. The data on efficacy and toxicity are presented. The
possible place of tetracycline derivatives within the overall strat¬
egy of RA treatment is also presented.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
VOLUME 24 • NUMBER 3 • AUGUST 1998 V
Cyclooxygenases as the Principal Targets for the Actions of
NSAIDs 501
Terry J. Smith
The recent identification, cloning, and characterization of two
cyclooxygenases has provided insight into how nonsteroidal anti
inflammatory drugs can beneficially inhibit prostaglandin pro¬
duction in inflammation but also produce side effects in the gut
and kidney. The subtle differences in the sites in which these
drugs bind the enzymes has allowed development of inhibitors
that exhibit selectivity for the inflammatory cyclooxygenase and
spare the housekeeping enzyme. This selectivity in theory should
enhance the therapeutic potential of these new drugs.
Oral Tolerization as a Treatment of Rheumatoid Arthritis 525
David E. Trentham
The basic science immunology community is quite accepting of
the phenomenon of oral tolerance induction in animals; however,
in contradistinction, the clinical community is somewhat agnostic
regarding oral tolerance. Progress in multiple sclerosis has not
been definitive and outcomes in RA have been modest at best.
Recent reports in animal models have suggested that oral inges
tion of autoantigen can have deleterious effects on the host.
Although those experiments have had a highly artificial frame¬
work, they are consistent with the possibility that oral antigen
therapy in human disease may be: (1) beneficial; (2) of no conse¬
quence; or (3) detrimental. An extremely open mind will hope¬
fully be applied to future research efforts.
Biologic Agents and Immunotherapy in Rheumatoid
Arthritis: Progress and Perspective 537
Wayne Jack Wallis, Daniel E. Furst, Vibeke Strand, and
Edward Keystone
Advances in our understanding of rheumatoid synovitis have
been coupled with increasingly refined methods from biotechnol¬
ogy to produce promising therapeutic agents. Monoclonal anti¬
bodies (MoAbs), recombinant cytokines, cytokine receptor fusion
proteins and other biologies have been elevated from the status
of novel reagents applied in phase I toxicity trials to, in some
cases, substantially evaluated and validated tools awaiting federal
regulatory approval. Biologic agents will soon be released for the
treatment of patients with RA. We review some of the most
promising preclinical work that supports a position of optimism
regarding the future of RA. We also speculate on the potential
role for biologies in future management of patients with RA.
Monoclonal Antibodies to CD4 567
Ferdinand C. Breed veld
Animal models of human autoimmune disease suggest that it
should be possible to reinduce self tolerance in these conditions
Vi CONTENTS
by the use of T cell directed therapies, in particular with anti
CD4 monoclonal antibodies (CD4 mAb). Many studies have
shown that CD4 mAb can prevent and in a treatment setting
suppress activity of these disease models, including collagen
induced arthritis.
Soluble Tumor Necrosis Factor Receptor (p75) Fusion
Protein (Enbrel) as a Therapy for Rheumatoid Arthritis 579
Larry W. Moreland
Soluble tumor necrosis factor (TNF) receptor fusion protein (p75)
(Enbrel) is a reversible inhibitor of the biologic effects of TNF.
Enbrel has been shown in placebo controlled trials to significantly
improve the signs and symptoms of rheumatoid arthritis. Clinical
trials are now in progress to assess the safety and efficacy of
Enbrel in combination with methotrexate in refractory rheuma¬
toid arthritis along with trials to compare Enbrel to methotrexate
in patients with early rheumatoid arthritis.
Anti Tumor Necrosis Factor a Monoclonal Antibody
Therapy for Rheumatoid Arthritis 593
Arthur F. Kavanaugh
Because it plays a central role in the immunopathogenesis of
rheumatoid arthritis (RA), TNF a is an attractive target for immu
nomodulatory therapy. In a number of rigorous studies, mono¬
clonal antibodies (mAb) specific for TNF a have proved effica¬
cious in patients with active RA. Data from these studies and
issues related to mechanisms of action, potential toxicity, and
future directions for this novel therapeutic approach are consid¬
ered in this review.
Interleukin 1 Receptor Antagonist 615
Barry Bresnihan and Gaye Cunnane
There are three members of the IL 1 gene family: IL lct, IL 13,
and IL lra. IL la and IL lfJ are both antagonist molecules with
many proinflammatory effects. IL lra is an antagonist molecule
that can inhibit the effect of IL la and IL ip by specifically
blocking the IL 1 receptor on target effector cells. IL la and IL
1(3 are considered to be pivotal cytokines in the pathogenesis of
many inflammatory diseases. Anti IL 1 treatment has been
shown to cause amelioration of arthritis in animal models and in
RA, suggesting that IL lra may be an important therapeutic op¬
tion in the future management of RA.
IL 10 as a Therapeutic Strategy in the Treatment of
Rheumatoid Arthritis 629
Edward Keystone, Janice Wherry, and Paul Grint
IL 10 has anti inflammatory and immunoregulatory properties
that suggest a potential therapeutic role in RA. IL 10 inhibits
CONTENTS vii
proinflammatory cytokine and chemokine production in addition
to blocking T cell responses to specific antigens. It acts primarily
through inhibition of costimulatory properties of macrophages.
IL 10 stimulates proliferation and differentiation of antibody
forming B cells. Preclinical studies in a variety of animal models,
including collagen induced arthritis, have shown that IL 10 is
effective in preventing or inhibiting inflammation and autoreac
tivity. Although in RA, circulating and synovial levels of IL 10
are increased, accumulated evidence suggests that there may be
a relative deficit of available IL 10. Moreover, exogenous addition
of IL 10 in vitro has been shown to affect the immunopathological
processes involved in RA. Preliminary studies of human recombi
nant IL 10 in patients with RA have demonstrated a trend to¬
wards efficacy with a good safety profile. Taken together, the data
support a therapeutic role for IL 10 in the treatment of RA.
T Cell Receptor Peptide Vaccination in the Treatment of
Rheumatoid Arthritis 641
S. Louis Bridges, Jr, and Larry W. Moreland
In several human T cell mediated autoimmune diseases and ani¬
mal models of such illnesses, T cell receptors (TCR) specific for
antigens that initiate or perpetuate the disease share a limited
number of variable region determinants. Vaccinations with pep
tides derived from over represented TCRs are effective treatment
for some of these disorders. RA is a chronic inflammatory disease
in which there is prominent T cell infiltration in the synovial
lining layer. TCR Vp3, V(J14, and Vpl7 have been found to
be over represented among IL 2 receptor positive T cells from
patients with RA. A phase II clinical trial in RA, using a combina¬
tion of three peptides derived from V(33, V(314, and V(317, has
yielded promising results. Larger clinical efficacy and safety stud¬
ies must be performed to determine if TCR peptide vaccination
will become a viable treatment alternative for patients with RA.
Methotrexate and Emerging Therapies 651
Joel M. Kremer
It is likely that all new therapeutic interventions will be used
with methotrexate in combination therapy. These combinations
may yield real therapeutic advances. The potential for end organ
toxicity, opportunistic infection, and malignancy will need to
be carefully monitored with long term, meticulously conducted
observational studies. Expense, ease of use, and perceived benefit
to risk ratio will determine which new agents become most com¬
monly prescribed with methotrexate.
Index 659
Subscription Information Inside back cover
viii CONTENTS
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV012135573 |
| callnumber-first | R - Medicine |
| callnumber-label | RC933 |
| callnumber-raw | RC933 |
| callnumber-search | RC933 |
| callnumber-sort | RC 3933 |
| callnumber-subject | RC - Internal Medicine |
| ctrlnum | (OCoLC)39702247 (DE-599)BVBBV012135573 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01787nam a2200445 cb4500</leader><controlfield tag="001">BV012135573</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">980902s1998 ad|| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)39702247</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV012135573</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC933</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Emerging therapies for rheumatoid arthritis</subfield><subfield code="c">Joel M. Kremer, guest ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">VIII S., S. 465 - 662</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Rheumatic disease clinics of North America</subfield><subfield code="v">24,3</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Reumatoïde artritis</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapieën</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Arthritis, Rheumatoid</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Rheumatoide Arthritis</subfield><subfield code="0">(DE-588)4076708-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Rheumatoide Arthritis</subfield><subfield code="0">(DE-588)4076708-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Rheumatoide Arthritis</subfield><subfield code="0">(DE-588)4076708-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kremer, Joel M.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Rheumatic disease clinics of North America</subfield><subfield code="v">24,3</subfield><subfield code="w">(DE-604)BV000625464</subfield><subfield code="9">24,3</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008219304&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-008219304</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV012135573 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T18:22:19Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-008219304 |
| oclc_num | 39702247 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-12 |
| owner_facet | DE-355 DE-BY-UBR DE-12 |
| physical | VIII S., S. 465 - 662 Ill., graph. Darst. |
| publishDate | 1998 |
| publishDateSearch | 1998 |
| publishDateSort | 1998 |
| publisher | Saunders |
| record_format | marc |
| series | Rheumatic disease clinics of North America |
| series2 | Rheumatic disease clinics of North America |
| spelling | Emerging therapies for rheumatoid arthritis Joel M. Kremer, guest ed. Philadelphia [u.a.] Saunders 1998 VIII S., S. 465 - 662 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Rheumatic disease clinics of North America 24,3 Reumatoïde artritis gtt Therapieën gtt Arthritis, Rheumatoid therapy Rheumatoide Arthritis (DE-588)4076708-5 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Rheumatoide Arthritis (DE-588)4076708-5 s Therapie (DE-588)4059798-2 s DE-604 Pharmakotherapie (DE-588)4076066-2 s Kremer, Joel M. Sonstige oth Rheumatic disease clinics of North America 24,3 (DE-604)BV000625464 24,3 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008219304&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Emerging therapies for rheumatoid arthritis Rheumatic disease clinics of North America Reumatoïde artritis gtt Therapieën gtt Arthritis, Rheumatoid therapy Rheumatoide Arthritis (DE-588)4076708-5 gnd Pharmakotherapie (DE-588)4076066-2 gnd Therapie (DE-588)4059798-2 gnd |
| subject_GND | (DE-588)4076708-5 (DE-588)4076066-2 (DE-588)4059798-2 (DE-588)4143413-4 |
| title | Emerging therapies for rheumatoid arthritis |
| title_auth | Emerging therapies for rheumatoid arthritis |
| title_exact_search | Emerging therapies for rheumatoid arthritis |
| title_full | Emerging therapies for rheumatoid arthritis Joel M. Kremer, guest ed. |
| title_fullStr | Emerging therapies for rheumatoid arthritis Joel M. Kremer, guest ed. |
| title_full_unstemmed | Emerging therapies for rheumatoid arthritis Joel M. Kremer, guest ed. |
| title_short | Emerging therapies for rheumatoid arthritis |
| title_sort | emerging therapies for rheumatoid arthritis |
| topic | Reumatoïde artritis gtt Therapieën gtt Arthritis, Rheumatoid therapy Rheumatoide Arthritis (DE-588)4076708-5 gnd Pharmakotherapie (DE-588)4076066-2 gnd Therapie (DE-588)4059798-2 gnd |
| topic_facet | Reumatoïde artritis Therapieën Arthritis, Rheumatoid therapy Rheumatoide Arthritis Pharmakotherapie Therapie Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008219304&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000625464 |
| work_keys_str_mv | AT kremerjoelm emergingtherapiesforrheumatoidarthritis |